FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.

We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.

19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaining 15 (44.1%) patients had DS > 3 on PET-1. 14/19 patients with DS ≤ 3 on PET-1 had no relapsed or refractory (r/r)-disease and were still alive at last follow-up. The other 5 patients had r/r-disease and 4 of these died. Except for two patients who had no r/r-disease, all other patients (13/15) with DS > 3 on PET-1 had r/r-disease and 12 of these subsequently died. Patients with DS ≤ 3 on PET-1 had significantly better progression free survival (PFS; HR: 5.7; p < 0.01) and overall survival (OS; HR: 5.0; p < 0.01) compared to patients with DS > 3 on PET-1. In addition, we demonstrated that patients with DS ≤ 4 on PET-0 tended to have longer PFS (HR: 3.6; p = 0.05).

Early FDG-PET/CT using the established DS after CAR T-cell therapy is a powerful tool to evaluate response to therapy.

Keywords

DLBCL, MCL, CAR T-cell, FDG-PET/CT

Publication History

Received: 30 December 2023

Accepted after revision: 07 March 2024

Article published online:
09 April 2024

• References

• 1 Barrington SF, Mikhaeel NG, Kostakoglu L. et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol Off J Am Soc Clin Oncol 2014; 32: 3048-3058
• 2 Pelosi E, Pregno P, Penna D. et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med 2008; 113: 578-590
• 3 Yang DH, Min JJ, Song HC. et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011; 47: 1312-1318
• 4 Juweid ME, Stroobants S, Hoekstra OS. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2007; 25: 571-578
• 5 Cheson BD, Fisher RI, Barrington SF. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Off J Am Soc Clin Oncol 2014; 32: 3059-3068
• 6 Neelapu SS, Locke FL, Bartlett NL. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377: 2531-2544
• 7 Schuster SJ, Bishop MR, Tam CS. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45-56
• 8 Ito K, Teng R, Schöder H. et al. 18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. J Nucl Med 2019; 60: 335-341 http://jnm.snmjournals.org/content/60/3/335.abstract
• 9 Boursier C, Perrin M, Bordonne M. et al. Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma. Clin Nucl Med 2022; 47: e152-e153
• 10 Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov 2018; 8: 1219-1226
• 11 Melenhorst JJ, Chen GM, Wang M. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 2022; 602: 503-509
• 12 Shah NN, Nagle SJ, Torigian DA. et al. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor –T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy 2018; 20: 1415-1418
• 13 Derlin T, Schultze-Florey C, Werner RA. et al. (18)F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Ann Nucl Med 2021; 35: 132-138
• 14 Cohen D, Luttwak E, Beyar-Katz O. et al. [¹⁸F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging 2022; 49: 953-962
• 15 Al Zaki A, Feng L, Watson G. et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv 2022; 6: 2867-2871
• 16 Kuhnl A, Roddie C, Kirkwood AA. et al. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv 2022; 6: 321-326
• 17 Breen WG, Hathcock MA, Young JR. et al. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. J Hematol Oncol 2022; 36
• 18 Westin JR, Tam CS, Borchmann P. et al. Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Blood 2019; 134: 4103 https://www.sciencedirect.com/science/article/pii/S0006497118620312
• 19 Iacoboni G, Simó M, Villacampa G. et al. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Ann Hematol 2021; 100: 2303-2310
• 20 Vercellino L, Di Blasi R, Kanoun S. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2020; 4: 5607-5615
• 21 Pinnix CC, Gunther JR, Dabaja BS. et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 2020; 4: 2871-2883
• 22 Jalbert JJ, Wu N, Chen CI. et al. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma. Adv Ther 2022; 39: 2630-2640
• 23 Locke FL, Miklos DB, Jacobson CA. et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2021; 386: 640-654
• 24 Lee JW, Baek M-J, Ahn TS. et al. Fluorine-18-fluorodeoxyglucose uptake of bone marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative surgical resection. Eur J Gastroenterol Hepatol 2018; 30: 187-194
• 25 Lee JW, Na JO, Kang DY. et al. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Clin Lung Cancer 2017; 18: 198-206
• 26 Prévost S, Boucher L, Larivée P. et al. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med 2006; 47: 559-565
• 27 Jin P, Bai M, Liu J. et al. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer. Front Immunol 2022; 13: 1004351
• 28 Nakamoto R, Zaba LC, Liang T. et al. Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. J Nucl Med 2021; 62: 1380-1383 http://jnm.snmjournals.org/content/62/10/1380.abstract
• 29 Georgi TW, Kurch L, Franke G-N. et al. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. J Cancer Res Clin Oncol 2023;
• 30 Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262